Conditions: Neovascular Age-Related Macular Degeneration
Keywords: AMD Wet AMD Neovascular AMD
Allocation: NON_RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 13
Healthy volunteers: no

Brief summary:
The objective of this study is to provide initial safety, tolerability and pharmacokinetics information of intravitreal administration of pegcetacoplan in order to support further development into larger Phase II studies for treatment of patients with AMD.

Detailed description:

Arms:
arm 1: 4 mg of pegcetacoplan 100 μL IVT injection arm 2: 10 mg of pegcetacoplan 100 μL IVT injection arm 3: 20 mg of pegcetacoplan 100 μL IVT injection

Interventions: intervention 1: Pegcetacoplan
Intervention descriptions: intervention 1: On treatment day, subjects will be administered a single 100 μL IVT injection of pegcetacoplan at the dose corresponding to their treatment assignment.

Protocol document: